KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Accounts Payables: 2010-2024

Historic Accounts Payables for Halozyme Therapeutics (HALO) over the last 15 years, with Dec 2024 value amounting to $10.2 million.

  • Halozyme Therapeutics' Accounts Payables rose 23.89% to $15.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.4 million, marking a year-over-year increase of 23.89%. This contributed to the annual value of $10.2 million for FY2024, which is 13.26% down from last year.
  • Latest data reveals that Halozyme Therapeutics reported Accounts Payables of $10.2 million as of FY2024, which was down 13.26% from $11.8 million recorded in FY2023.
  • In the past 5 years, Halozyme Therapeutics' Accounts Payables registered a high of $17.7 million during FY2022, and its lowest value of $1.5 million during FY2021.
  • Its 3-year average for Accounts Payables is $13.3 million, with a median of $11.8 million in 2023.
  • Per our database at Business Quant, Halozyme Therapeutics' Accounts Payables crashed by 70.03% in 2020 and then skyrocketed by 1,048.15% in 2022.
  • Over the past 5 years, Halozyme Therapeutics' Accounts Payables (Yearly) stood at $1.9 million in 2020, then fell by 20.07% to $1.5 million in 2021, then spiked by 1,048.15% to $17.7 million in 2022, then crashed by 33.22% to $11.8 million in 2023, then dropped by 13.26% to $10.2 million in 2024.